Non-Covalent BTK Inhibitors in the Treatment of CLL: Nemtabrutinib

February 3, 2023

By Susan O'Brien, MD
Alexey Danilov, MD, PhD

News

Video

Dr Seema Ali Bhat continues the conversation on non-covalent BTK inhibitors in CLL treatment with a look at nemtabrutinib and data from the BELLWAVE-001 study.

EP: 1.Mechanism of Action of BTK Inhibitors in Chronic Lymphocytic Leukemia

EP: 2.Selecting the Appropriate BTK Inhibitor for Frontline Treatment of CLL

EP: 3.BTK Inhibitors for the Treatment of Relapsed CLL

EP: 4.Comparing BTK Inhibitors in the Treatment of Relapsed CLL

EP: 5.Selecting an Appropriate BTK Inhibitor for the Treatment of Relapsed CLL

EP: 6.Non-Covalent BTK Inhibitors in the Treatment of CLL: Pirtobrutinib

Now Viewing

EP: 7.Non-Covalent BTK Inhibitors in the Treatment of CLL: Nemtabrutinib

EP: 8.Fixed-Duration Venetoclax in the Treatment of CLL

EP: 9.Role of Venetoclax in Patients with High-Risk CLL

EP: 10.Sequencing Therapies in CLL

EP: 11.Emerging Therapies in CLL

EP: 12.Unmet Needs and Future Perspectives in the Treatment of CLL

EP: 13.Recap: BTK Inhibition and Treatment Options in Chronic Lymphocytic Leukemia

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!